Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses

不依赖于中和抗体的SARS-CoV-2控制与鼻内疫苗诱导的CD8+ T细胞反应相关

阅读:5
作者:Hiroshi Ishii ,Takushi Nomura ,Hiroyuki Yamamoto ,Masako Nishizawa ,Trang Thi Thu Hau ,Shigeyoshi Harada ,Sayuri Seki ,Midori Nakamura-Hoshi ,Midori Okazaki ,Sachie Daigen ,Ai Kawana-Tachikawa ,Noriyo Nagata ,Naoko Iwata-Yoshikawa ,Nozomi Shiwa ,Tadaki Suzuki ,Eun-Sil Park ,Maeda Ken ,Taishi Onodera ,Yoshimasa Takahashi ,Kohji Kusano ,Ryutaro Shimazaki ,Yuriko Suzaki ,Yasushi Ami ,Tetsuro Matano

Abstract

Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19) pandemic. Currently developed vaccines inducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-antigen-specific neutralizing antibodies (NAbs) are effective, but the appearance of NAb-resistant S variant viruses is of great concern. A vaccine inducing S-independent or NAb-independent SARS-CoV-2 control may contribute to containment of these variants. Here, we investigate the efficacy of an intranasal vaccine expressing viral non-S antigens against intranasal SARS-CoV-2 challenge in cynomolgus macaques. Seven vaccinated macaques exhibit significantly reduced viral load in nasopharyngeal swabs on day 2 post-challenge compared with nine unvaccinated controls. The viral control in the absence of SARS-CoV-2-specific NAbs is significantly correlated with vaccine-induced, viral-antigen-specific CD8+ T cell responses. Our results indicate that CD8+ T cell induction by intranasal vaccination can result in NAb-independent control of SARS-CoV-2 infection, highlighting a potential of vaccine-induced CD8+ T cell responses to contribute to COVID-19 containment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。